Tu banner alternativo

Icalcaprant

In today's world, Icalcaprant has become an issue that is gaining more and more relevance in various areas of society. From politics to science, culture and technology, Icalcaprant has generated great interest and debate among experts and citizens alike. No matter if it is a historical figure, a scientific discovery or a cultural phenomenon, Icalcaprant has captured the attention of millions of people around the world. In this article, we will explore in detail the different approaches and perspectives that exist around Icalcaprant, and examine its impact on our daily lives.

Tu banner alternativo
Icalcaprant
Clinical data
Other namesCVL-354
Routes of
administration		Oral administration
Drug classOpioid antagonist; κ-Opioid receptor antagonist
Identifiers
  • 4-methyl]phenoxy]benzamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H26N4O3
Molar mass406.486 g·mol−1
3D model (JSmol)
  • CN1C=C(C(=N1)OC)2CCCN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)N
  • InChI=1S/C23H26N4O3/c1-26-15-20(23(25-26)29-2)21-4-3-13-27(21)14-16-5-9-18(10-6-16)30-19-11-7-17(8-12-19)22(24)28/h5-12,15,21H,3-4,13-14H2,1-2H3,(H2,24,28)/t21-/m0/s1
  • Key:OBDLEFCGVHQDFR-NRFANRHFSA-N

Icalcaprant[1] (developmental code name CVL-354) is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[2][3] It is taken by mouth.[2]

It acts as a selective antagonist of the κ-opioid receptor.[2][3] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.[3]

It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie).[2][4] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[2]

See also

References

  1. ^ "Icalcaprant (CVL-354)". AbbVie. Retrieved 2024-08-15.
  2. ^ a b c d e "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.
  3. ^ a b c "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.
  4. ^ "AbbVie Completes Acquisition of Cerevel Therapeutics". AbbVie News Center. Retrieved 2025-05-07.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia